Literature DB >> 2740417

Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals.

K A Grant1, W L Woolverton.   

Abstract

Ca-acetyl homotaurine (Ca-AOTA) has been proposed as an adjunct for ethanol detoxification. The purpose of the present experiment was to determine whether Ca-AOTA would be predicted to have abuse potential. Rhesus monkeys that were experienced in the intravenous self-administration of cocaine (n = 2) or pentobarbital (n = 2) were given the opportunity to self-administer various doses of Ca-AOTA or its vehicle (0.9% saline). Ca-AOTA (1.0-10.0 mg/kg/injection, intravenously) was not self-administered above saline levels. The discriminative stimulus effects of Ca-AOTA were evaluated in a drug discrimination procedure in which animals were trained to make one response after a training drug and a different response after saline. Rhesus monkeys trained to discriminate d-amphetamine (n = 3) or pentobarbital (n = 3) from saline were tested with doses of Ca-AOTA ranging from 10 to 100 mg/kg (PO by nasogastric tube) and at 3 different pretreatment times (1, 2, or 4 hr). Ca-AOTA failed to engender drug-appropriate responding at any dose or pretreatment condition in either group of monkeys. In addition, Ca-AOTA was tested in 4 pigeons trained to discriminate pentobarbital from saline. Ca-AOTA administration did not result in pentobarbital-appropriate responding in doses ranging from 30-300 mg/kg (IM) and pretreatment times ranging from 30 to 240 min. The lack of both reinforcing properties and discriminative stimulus properties similar to d-amphetamine or pentobarbital suggests that Ca-AOTA has little or no abuse potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2740417     DOI: 10.1016/0091-3057(89)90005-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Role of altered structure and function of NMDA receptors in development of alcohol dependence.

Authors:  József Nagy; Sándor Kolok; András Boros; Péter Dezso
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 2.  Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

Authors:  M I Wilde; A J Wagstaff
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

4.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

Review 5.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 6.  Clinical pharmacokinetics of acamprosate.

Authors:  S Saivin; T Hulot; S Chabac; A Potgieter; P Durbin; G Houin
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 7.  Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

Authors:  Julia M A Sinclair; Sophia E Chambers; Celia J Shiles; David S Baldwin
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

8.  The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine.

Authors:  Andrew J McGeehan; M Foster Olive
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Safety and efficacy of acamprosate for the treatment of alcohol dependence.

Authors:  Stephanie L Yahn; Lucas R Watterson; M Foster Olive
Journal:  Subst Abuse       Date:  2013-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.